NFL BIOSCIENCES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.892 EUR | +3.96% |
|
-9.26% | +31.39% |
| Apr. 12 | Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... |  |
| Apr. 12 | NFL Biosciences: successful capital increase | CF |
Business Summary
At the end of 2022, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Bruno Lafont
FOU | Founder | - | 06-08-31 |
Ignacio Faus
CEO | Chief Executive Officer | - | 21-05-18 |
Guillaume Audema
DFI | Director of Finance/CFO | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yannick Plétan
BRD | Director/Board Member | - | 21-05-18 |
Ignacio Faus
CEO | Chief Executive Officer | - | 21-05-18 |
Bruno Lafont
FOU | Founder | - | 06-08-31 |
Francis Ahner
BRD | Director/Board Member | - | 21-05-18 |
Michel Huc
BRD | Director/Board Member | - | 21-05-18 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 7,606,769 | 5,182,266 ( 68.13 %) | 0 | 68.13 % |
Company contact information
NFL Biosciences SAS
199 rue Hélène Boucher
34170, Castelnau-le-Lez
+33 4 11 93 76 67
http://www.nflbiosciences.com
Sector
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.82
EUR
Average target price
4.2
EUR
Spread / Average Target
+130.77%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.39% | 15.75M | |
| -2.41% | 103B | |
| +1.74% | 95.28B | |
| +1.46% | 22.15B | |
| -15.62% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.01% | 16.05B | |
| +5.28% | 13.68B | |
| +35.00% | 12.17B |
- Stock Market
- Equities
- ALNFL Stock
- Company NFL Biosciences
